Gleam
United States· Est.
AI‑powered platform that speeds drug discovery and oncology and immunology therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered platform that speeds drug discovery and oncology and immunology therapeutics.
Technology Platform
A generative AI engine that integrates transformer‑based models with large biological and chemical datasets to design and optimize novel therapeutic molecules.
Opportunities
Rapidly expanding AI‑driven drug discovery market and potential partnerships with pharma for accelerated candidate development.
Risk Factors
Unproven clinical translation of AI‑generated candidates and reliance on high‑quality data for model performance.
Competitive Landscape
Competes with AI biotech firms like Insilico Medicine and Exscientia; differentiation through an end‑to‑end workflow coupling design and safety prediction.